Nonclinical Studies Subcommittee John Doull, M.D., Ph.D., Chair Advisory Committee for Pharmaceutical Science November 15, 2000.

Slides:

Advertisements

Similar presentations

How to Build a Productive Relationship with NIH Topics Know your disease Know the NIH and NINDS Have realistic expectations Advocate for stronger NIH and.

Advertisements

ICH Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC) Overview and Update Robert H. King, Sr. Office of Pharmaceutical.

 Definition  The demand continues  Is an academic career a good fit for you ?  Academia: many roles outside classroom  Role of faculty member ◦ Teaching.

EISWG The Environmental Information Services Working Group of the NOAA Science Advisory Board Raymond J. Ban April 22, 2009.

December 14, FDA Advisory Committee for Pharmaceutical Science Nonclinical Studies Subcommittee Efficient advancement to clinical trials Jack A.

SUBPART D PRESENTATION Inaugural meeting of the Pediatric Ethics Subcommittee (PES) of the Pediatric Advisory Committee (PAC); part of the inaugural meeting.

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science Introduction & FDA Objectives Gaithersburg Hilton December 14, 1999 T:\NCSS\ PPT.

Chinese TAIPEI APEC EWG 47 (2014) China 1 All rights reserved. APEC Network on Development of Biomass-derived Fuel Gas System for Zero-emission Vehicles.

Evolution of ICCVAM ◊National Toxicology Program Develop and validate improved test methods ◊NIH Revitalization Act: P.L Develop and.

FDA Advisory Committee Training An Industry Representative Perspective Alison Lawton Sr. VP Regulatory Affairs Genzyme Corporation.

Working in the Biotech/Pharmaceutical Industry October 11, 2007 Irene Griff, Ph.D. Program Manager Johns Hopkins Medical School Baltimore, MD.

Critical Path Opportunities for Biologics Products Jesse L. Goodman, M.D. M.P.H. Director Kathryn M. Carbone, M.D. Associate Director for Research Center.

Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.

A PPP managed by FNIH Partners are NIH, FDA, CMS, and private industry Barbara B. Mittleman, M.D. Director, NIH PPP Program Bioinformatics Forum March.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.

The Innovative Medicines Initiative (IMI) High level the IMI Concept, Strategic Research Agenda and Call topics Eva Lindgren.

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

PhUSE Computational Science Working Groups Solutions Through Collaboration.

*The views expressed in this presentation are those of the presenter’s and do not necessarily represent the views of the U.S. Food and Drug Administration.

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

Research Peer-Review at CDER Past and Present Jerry M. Collins, Ph.D. Director, Laboratory of Clinical Pharmacology, OTR Acting Director, Division of Applied.

Office of Pharmaceutical Sciences

HESI ILSI Health and Environmental Sciences Institute HESI PROJECT COMMITTEE ON DOSE-DEPENDENT TRANSITIONS IN MECHANISMS OF TOXICITY NANCY G. DOERRER,

1 2-Topic Imaging Workshop: (1)Standards for Imaging Endpoints in Clinical Trials (2) Manufacturing of PET Radiopharmaceutical Products Wendy R. Sanhai,

June Jandil Meeting June 2012 Power Committee and Council Meeting Regional Technical Forum Membership

Introducing the Durban Climate Change Partnership January 2012.

DESIGNING A PROGRAM FOR REVIEW OF CDER LABORATORY RESEARCHERS Keith Webber, Ph.D. Acting Deputy Director OPS/CDER/FDA.

FDA Office of Orphan Products Development

UPDATE: Nonclinical Reproductive Toxicity Information in Assessing Human Risk Joseph J. DeGeorge Ph.D. Associate Director for Pharmacology and Toxicology.

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

1 Nanoscale Materials Stewardship Program Environmental Summit May 20, 2008 Jim Alwood Chemical Control Division Office of Pollution Prevention and Toxics.

NCSS Fact Finding Cardiotoxicity Expert Working Group Kendall B. Wallace (University of Minnesota) –Chair Elizabeth Murphy (NIEHS, NIH) I.Y. Rosenblum.

FDA Public Meeting Preparation for the ICH Meetings in Tokyo, Japan, Including Progress on the Common Technical Document and Possibilities for New Topics.

HIV-1 Resistance Testing in Drug Development Antiviral Drugs Advisory Committee Meeting November 2-3, 1999.

FDA ADVISORY COMMITTEES Mary A Foulkes, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, FDA FDA/Industry.

SMC and the role of Public Involvement Action Duchenne Scottish Mini Conference 4 December 2015 Lindsay Lockhart Public Involvement Officer.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

ICH Quality Topics Update

PhUSE Computational Science Working Groups Solutions Through Collaboration.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.

Cardiotox Expert Working Group Report to the NCSS September 9 & 10, 2002.

Creating the Path for Innovative New Therapies Raymond L. Woosley, MD, PhD President, The Critical Path Institute.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Peter Karlton 1 Regulatory Challenges A Diversity of Considerations Ethical Cultural Regulatory standards Strained resources Competing priorities Training.

Joint Health IT Committee Meeting Precision Medicine Task Force March 10, 2016 Leslie Kelly Hall, Co-Chair Andy Wiesenthal, Co-Chair.

Medical Writing Special Interest Area Community (SIAC) Medical Communications March Workshop 2012 David Clemow SIAC Chair Melissa Ossanna Communications.

OVERVIEW OF THE WORKFORCE DEVELOPMENT DOMAIN TASK FORCE APRIL 16, 2015 Joan D. Nagel, M.D., M.P.H. Program Director, Division of Clinical Innovation National.

Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.

Rural Medical Educator’s Interest Group of the National Rural Health Association Joe Florence, MD Director of Rural Programs – East Tennessee State University.

EUA Report on Doctoral Programmes Progress Report BFUG meeting Helsinki, 13 October 2006.

Version: 27 May 2007 New Models for Collaboration: Patients as Drivers and Partners in Neurological Research Integrating Patient Input Within the Drug.

Interagency Oncology Task Force (IOTF)

Department of Medicine

Michelle Limoli, Pharm.D.

Report by the VICH Steering Committee on issues raised by Forum members during the 1st Outreach Forum meeting Hervé Marion, DVM VICH Secretariat.

Community Engagement Subcommittee – Update

Welcome to the Meeting of the Drone Advisory Committee

PhUSE Computational Science

Rick McGee, PhD and Bill Lowe, MD Faculty Affairs and NUCATS

Scientific competence Communication and transparency

PhUSE Computational Science Working Groups

ICH Q9: Quality Risk Management

ICH Q9: Quality Risk Management

FDA Tox Working Group Which goals of the FDA Roadmap are most important to FDA stakeholders? Integration of predictive technologies Replacing animal tests.

Cancer Symptom Trials (CST) Membership

What is FASEB? A federation of 30 societies

PMB Review Update PO’s Forum

Cancer Symptom Trials (CST) Membership

Presentation transcript:

Nonclinical Studies Subcommittee John Doull, M.D., Ph.D., Chair Advisory Committee for Pharmaceutical Science November 15, 2000

Nonclinical Studies Subcommittee Functions:  To provide advice on improved scientific approaches to nonclinical drug development and regulation  A means to foster collaboration among FDA, industry, academia, and the public

Objectives 1. To recommend approaches and mechanisms to improve:  NC information for effective drug development  predictivity of NC tests for human outcomes  linkage between NC and clinical studies and 2. To facilitate collaborative approaches to advancing the science and regulation of drug development

Collaborators  FDA  CDER  CBER  NCTR  Industry  PhRMA  BIO  Academia  Public Institutions (NIH)

Subcommittee Membership  John Doull, Univ. Kansas (Chair)  James MacGregor, CDER  David Essayan, CBER  Daniel Casciano, NCTR  Jack Reynolds, PhRMA  Joy Cavagnaro  Raymond Tennant, NIH  Jay Goodman, Michigan State University  Jack Dean, Sanofi-Synthelabo  Gloria Anderson, ACPS (Morris Brown Univ.)

FY2000 Meetings  12/14/99 Meeting--Identified General Focus  Biomarkers of Toxicity  Noninvasive technologies to link nonclinical and clinical studies  3/9/00--Specific topics for EWGs  Biomarkers of cardiac toxicity  Biomarkers of vasculitis  PET application to small animal studies

Subcommittee Role: Identify and recommend focus areas Identify experts in focus areas; form expert working groups (EWGs) with nominations from: Federal Register announcements (Public) FDA and “Stakeholders” (Collaborators) Professional Societies EWGs identify opportunities for collaborations and define objectives Steering committee to collaborative projects Support workshops and facilitate reports

EWG Nominations Requests  FR Notice Published 7/26/00  Letters to Scientific Societies  FDA announcements  Subcommittee contacts  Announcement at public meetings (e.g., Toxicology Forum)

EWG Status  Nominations Submission Deadline 9/29/00  Twenty-six nominations received  FDA reviews nominations  Selection of members in process (Nov/Dec)  Joint NCSS/EWG meeting planned  January 2001